While large pharmaceutical companies are filled with a wide breadth of smart people, smaller biotech firms offer a different kind of intellectual environment. They feature the same degree of brilliance, but it's concentrated in a much more focused organization, creating a unique depth of talent.

While scientific acumen is valuable, the most critical trait for a biotech CEO is perseverance. The role involves weathering constant challenges where everyone—the board, investors, employees—can seem to be against you. An unwavering focus on the patient mission is essential to push through.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

While large pharma companies invested heavily in RNAi and failed to produce candidates, Alnylam maintained a singular focus. They pushed their technology into human trials to learn and validate it, ultimately succeeding where better-funded competitors with a less focused, product-driven approach failed.

Many scientists are driven by pure curiosity. However, the mindset that pushes an academic toward entrepreneurship is a relentless focus on reaching a definitive conclusion—a 'yes or no' answer. This goal-oriented drive to translate a concept into a real-world application is a key founder trait in biotech.

In crowded fields like oncology, most companies flock to a few validated ideas, like kids chasing a soccer ball. Delpha Therapeutics' CEO Kevin Marks argues the real opportunity lies in pioneering novel biology in the wide-open parts of the field, creating a strategic advantage and potential scarcity effect.